With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

ESTEVE CDMO, a global CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, began a $15.5 ...

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

BioDuro and Cenra launch joint venture to expand resilient global API manufacturing capacity: Irvine Californa Thursday, March 5, 2026, 14:00 Hrs [IST] BioDuro, a globally trusted ...

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

Amazon Filters is a leading manufacturer of bespoke filter housings and high-performance filter media used in the manufacture of Active Pharmaceutical Ingredients (API's) - vital building blocks for ...

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.